Cay10594 is primarily used in biochemical and pharmacological research as a selective agonist for the GPR119 receptor. Activation of GPR119 has been linked to the regulation of glucose homeostasis and insulin secretion, making this compound a valuable tool in the study of type 2 diabetes and metabolic disorders. Researchers use Cay10594 to investigate pathways involved in incretin hormone release, such as GLP-1, which plays a key role in glucose-dependent insulin release. Due to its ability to stimulate insulin secretion only in the presence of elevated glucose levels, it is also explored for its potential in developing glucose-lowering therapies with a reduced risk of hypoglycemia. Additionally, Cay10594 has been employed in studies examining appetite regulation and energy balance, as GPR119 activation may influence food intake and body weight. Its application remains largely confined to preclinical research, aiding in target validation and mechanistic studies related to metabolic disease.